Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen–specific CD8+ T-cell function in Hodgkin lymphoma patients
The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
In Hodgkin lymphoma (HL), the malignant Hodgkin Reed-Sternberg (HRS) cells constitute only 0.5% of 10% of the diseased tissue. The surrounding cellular infiltrate is enriched with T cells that are hypothesized to modulate antitumor immunity. We show that a marker of regulatory T cells, LAG-3, is strongly expressed on infiltrating lymphocytes present in proximity to HRS cells. Circulating regulatory T cells (CD4+ CD25hi CD45 ROhi, CD4+ CTLA4hi, and CD4+ LAG-3hi) were elevated in HL patients with active disease when compared with remission. Longitudinal profiling of EBV-specific CD8+ T-cell responses in 94 HL patients revealed a selective loss of interferon-γ expression by CD8+ T cells specific for latent membrane proteins 1 and 2 (LMP1/2), irrespective of EBV tissue status. Intratumoral LAG-3 expression was associated with EBV tissue positivity, whereas FOXP3 was linked with neither LAG-3 nor EBV tissue status. The level of LAG-3 and FOXP3 expression on the tumor-infiltrating lymphocytes was coincident with impairment of LMP1/2-specific T-cell function. In vitro pre-exposure of peripheral blood mononuclear cells to HRS cell line supernatant significantly increased the expansion of regulatory T cells and suppressed LMP-specific T-cell responses. Deletion of CD4+ LAG-3+ T cells enhanced LMP-specific reactivity. These findings indicate a pivotal role for regulatory T cells and LAG-3 in the suppression of EBV-specific cell-mediated immunity in HL.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“LAG3 can activate the maturation and stimulation of DCs through the regulation of intracellular phosphorylation protein and promote chemokines like tumor necrosis factor α (TNF‐α) [328].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [328]
Citations
Cites
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151 · cited 2×
“Long-term remission 39 290 (74) 106 (14-106) .”
Fitzgerald, M., Hayward, I. P., Thomas, A. C., Campbell, J. H., & CAMPBELL, G. R. (1995) · Cited by 2,552
Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues
Jaffe, E. S. (2003) · Cited by 2,141
A Prognostic Score for Advanced Hodgkin's Disease
Hasenclever, D., Diehl, V., Armitage, J. O., Assouline, D., Björkholm, M., Brusamolino, E., Canellos, G. P., Carde, P., Crowther, D., Cunningham, D., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392104 · Cited by 1,736
Role of LAG-3 in Regulatory T Cells
Huang, C.-T., Workman, C. J., Flies, D., Pan, X., Marson, A. L., Zhou, G., Hipkiss, E. L., Ravi, S., Kowalski, J., Levitsky, H. I., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.08.010 · Cited by 1,325
Jonuleit, H., Schmitt, E., Stassen, M., Tuettenberg, A., Knop, J., & Enk, A. H. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.11.1285 · Cited by 1,255
Natural regulatory T cells in infectious disease
Belkaid, Y., & Rouse, B. T. (2005) · Nature Immunology · doi:10.1038/ni1181 · Cited by 1,035
Induction and mechanism of action of transforming growth factor‐β‐secreting Th3 regulatory cells
Weiner, H. L. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1820117.x · Cited by 846
Diehl, V., Franklin, J., Pfreundschuh, M., Lathan, B., Paulus, U., Hasenclever, D., Tesch, H., Herrmann, R., Dörken, B., Müller-Hermelink, H.-K., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022473 · Cited by 838
Cited by
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
McLane, L. M., Abdel-Hakeem, M. S., & Wherry, E. J. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055318 · Cited by 1,975
“Indeed, tumor-specific CD8 T cells display hallmarks of T cell exhaustion and dysfunction in mouse models (24, 25) and human cancers including, but not limited to, melanoma (26–30), chronic myeloid leukemia (24), ovarian cancer (31), non–small cell carcinoma (32, 33), Hodgkin lymphoma (34), and chronic lymphocytic leu…”
BackgroundThe biology of Hodgkin's lymphoma
Küppers, R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2542 · Cited by 688
“A considerable fraction of infiltrating CD4 + T cells are T Reg cells, which have been shown to have immunosuppressive activity on Hodgkin's lymphoma-infiltrating cytotoxic T cell”
BackgroundThe Immunology of Epstein-Barr Virus–Induced Disease
Taylor, G. S., Long, H. M., Brooks, J. M., Rickinson, A. B., & Hislop, A. D. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112326 · Cited by 602
“However, LMP2-specific CD8+ T cells are frequently detected in the blood of HL and NPC patients (201, 206, 210, 211), although sometimes at a reduced frequency (212).”
Grosso, J. F., Kelleher, C. C., Harris, T. J., Maris, C. H., Hipkiss, E. L., De Marzo, A., Anders, R., Netto, G., Getnet, D., Bruno, T. C., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31184 · Cited by 547
Zarek, P. E., Huang, C.-T., Lutz, E. R., Kowalski, J., Horton, M. R., Linden, J., Drake, C. G., & Powell, J. D. (2008) · Blood · doi:10.1182/blood-2007-03-081646 · Cited by 515
“LAG-3 expression has been noted on tumor infiltrating lymphocytes that have the capacity to suppress anti-tumor specific CD8 T cells.(30) The fact that the tumor microenvironment contains relatively high levels of adenosine suggests that tumor-derived adenosine may promote the generation of these regulatory cells.”
Background
Metadata
- Authors
- Gandhi, M. K., Lambley, E., Duraiswamy, J., Dua, U., Smith, C., Elliott, S., Gill, D., Marlton, P., Seymour, J., & Khanna, R.
- Affiliations
- The University of Melbourne (AU)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2006-10-01
- Volume
- 108
- Issue
- 7
- Pages
- 2280-2289
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2086419697
- Cited by
- 255
- References
- 57
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 17 · 2023: 19 · 2022: 18 · 2021: 20 · 2020: 21 · 2019: 17 · 2018: 9 · 2017: 8 · 2016: 10 · 2015: 20 · 2014: 9 · 2013: 5 · 2012: 8
- FWCI
- 4.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Keywords
- LAG-3, Hodgkin's disease, tumor-infiltrating lymphocytes, regulatory T cells, latent membrane protein 1, latent membrane protein 2, EBV-specific CD8+ T cells, interferon-gamma, Foxp3, CTLA-4, antitumor immunity, T cell suppression, Reed-Sternberg cells, remission
- MeSH terms
- Lymphocyte Activation Gene 3 Protein, Adolescent, Adult, Aged, Child, Child, Preschool, Female, Hodgkin Disease, Humans, Male, Middle Aged, Remission Induction, Viral Matrix Proteins, Antigens, CD, Gene Expression Regulation, Neoplastic, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen–specific CD8+ T-cell function in Hodgkin lymphoma patients. https://app.cochat.ai/papers/10.1182/blood-2006-04-015164
- The paper
- Gandhi, M. K., Lambley, E., Duraiswamy, J., Dua, U., Smith, C., Elliott, S., Gill, D., Marlton, P., Seymour, J., & Khanna, R. (2006). Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen–specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood. https://doi.org/10.1182/blood-2006-04-015164
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.